GlassScriptPhysician profile
David A Woodard
NPI 1598736670
$16,056.49
in general payments reported to CMS, 2019-2025
26 companies · $2,542 in 2025
The $2,542 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $536 · 2021: $8,422 · 2022: $885 · 2023: $1,563 · 2024: $700 · 2025: $2,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770 · Travel and Lodging: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.32 |
| Travel and Lodging | $2,034.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $8,695.67 | 2019-2023 | |
| Abbott Laboratories | $4,012.48 | 2019-2025 | Aveir, Accent, Assurity |
| Stryker Corporation | $891.54 | 2025 | Salvation, Inspace, Blueprint Patient Specific Instrumentation |
| Medtronic, INC. | $671.29 | 2021-2024 | Micra, Anteralign Spinal System With Titan Nanolock Surface Technology |
| E.R. Squibb & Sons, L.L.C. | $475.58 | 2022-2024 | Eliquis, Camzyos |
| Pfizer INC. | $179.31 | 2022-2024 | |
| Impulse Dynamics (USA) INC. | $179.18 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $146.82 | 2019-2022 | |
| Baxter Healthcare | $100.54 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $86.99 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $81.53 | 2020-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.01 | 2020-2025 | Lifevest |
| Atricure, INC. | $73.18 | 2023 | |
| Amgen INC. | $73.15 | 2022-2024 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $53.44 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $36.02 | 2019 | |
| Boston Scientific Corporation | $28.62 | 2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $27.90 | 2022-2023 | Xarelto |
| Cardiva Medical, INC. | $27.14 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $26.54 | 2022 | |
| Merck Sharp & Dohme LLC | $23.96 | 2024 | Verquvo |
| Abiomed | $21.48 | 2024 | Impella |
| Esperion Therapeutics, INC. | $20.48 | 2024 | Nexletol |
| Ethicon US, LLC | $15.26 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $14.15 | 2022 | |
| Philips North America LLC | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Woodard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.